Skip to Main content Skip to Navigation
Journal articles

Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia

Abstract : We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
Document type :
Journal articles
Complete list of metadatas

Cited literature [21 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-01996207
Contributor : Rene Valero <>
Submitted on : Monday, January 28, 2019 - 11:15:17 AM
Last modification on : Wednesday, August 19, 2020 - 12:08:22 PM
Long-term archiving on: : Monday, April 29, 2019 - 3:14:09 PM

File

case Report anti LPL antibodie...
Files produced by the author(s)

Identifiers

Collections

Citation

Sophie Béliard, Mathilde Di Filippo, Gilles Kaplanski, Rene Valero. Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia. Journal of clinical lipidology, Elsevier, 2018, 12 (4), pp.883-887. ⟨10.1016/j.jacl.2018.04.011⟩. ⟨hal-01996207⟩

Share

Metrics

Record views

194

Files downloads

508